XML 25 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholder Equity (Deficit) - USD ($)
$ in Millions
Total
Dun & Bradstreet Corp
Total stockholder equity (deficit)
Total stockholder equity (deficit)
Dun & Bradstreet Corp
Common stock 
Common stock 
Dun & Bradstreet Corp
Capital surplus
Capital surplus
Dun & Bradstreet Corp
(Accumulated deficit) retained earnings
(Accumulated deficit) retained earnings
Dun & Bradstreet Corp
Treasury stock
Treasury stock
Dun & Bradstreet Corp
Cumulative translation adjustment
Cumulative translation adjustment
Dun & Bradstreet Corp
Defined benefit postretirement plans
Defined benefit postretirement plans
Dun & Bradstreet Corp
Cash flow hedging derivative
Cash flow hedging derivative
Dun & Bradstreet Corp
Non-controlling interest
Non-controlling interest
Dun & Bradstreet Corp
Tax benefit (expense) related to pension adjustment $ (22.2)                                      
Foreign currency translation adjustments, tax expense (benefit) 0.1                                      
Derivative financial instruments, tax expense (benefit) 0.1                                      
Balance at beginning of period at Dec. 31, 2018 (13.5) $ (689.9) $ (13.5) $ (705.8) $ 0.0 $ 0.8 $ 0.0 $ 332.8 $ (13.5) $ 3,325.0 $ 0.0 $ (3,310.3) $ 0.0 $ (235.5) $ 0.0 $ (818.3) $ 0.0 $ (0.3) $ 0.0 $ 15.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Net income (loss) (74.8) [1]   (75.6)           (75.6)                   0.8  
Payment to non-controlling interest (0.1)                                   (0.1)  
Equity-based compensation plans 11.7   11.7       11.7                          
Pension adjustments, net of tax expense (benefit) 65.4   65.4                       65.4          
Change in cumulative translation adjustment, net of tax expense (income) 5.9 [2]   5.7                   5.7           0.2  
Derivative financial instruments, net of tax expense (benefit) (0.1) [1],[3]   (0.1)                           (0.1)      
Balance at end of period at Feb. 07, 2019 (681.9)   (698.7)   0.8   344.5   3,249.4   (3,310.3)   (229.8)   (752.9)   (0.4)   16.8  
Tax benefit (expense) related to pension adjustment 7.3                                      
Foreign currency translation adjustments, tax expense (benefit) 1.8                                      
Derivative financial instruments, tax expense (benefit) 0.4                                      
Balance at beginning of period at Dec. 31, 2018 (13.5) $ (689.9) (13.5) $ (705.8) 0.0 $ 0.8 0.0 $ 332.8 (13.5) $ 3,325.0 0.0 $ (3,310.3) 0.0 $ (235.5) 0.0 $ (818.3) 0.0 $ (0.3) 0.0 $ 15.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Net income (loss) (553.7) [1],[4]   (560.1)           (560.1)                   6.4  
Take-Private Transaction 2,108.7   2,048.4       2,048.4                       60.3  
Capital contribution 100.0   100.0       100.0                          
Payment to non-controlling interest (5.7)                                   (5.7)  
Equity-based compensation plans 68.0   68.0       68.0                          
Preferred dividend (96.1)   (96.1)       (96.1)                          
Accretion - Series A Preferred Stock (3.4)   (3.4)       (3.4)                          
Pension adjustments, net of tax expense (benefit) (24.0)   (24.0)                       (24.0)          
Change in cumulative translation adjustment, net of tax expense (income) (1.9) [1],[2]   0.9                   0.9           (2.8)  
Derivative financial instruments, net of tax expense (benefit) (1.1) [1],[3]   (1.1)                           (1.1)      
Balance at end of period at Dec. 31, 2019 1,577.3   1,519.1   0.0   2,116.9   (573.6)   0.0   0.9   (24.0)   (1.1)   58.2  
Tax benefit (expense) related to pension adjustment 32.4                                      
Foreign currency translation adjustments, tax expense (benefit) 2.9                                      
Derivative financial instruments, tax expense (benefit) (0.2)                                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Net income (loss) (111.6) [1],[4]   (116.5)           (116.5)                   4.9  
Issuance of Class A Common Stock in IPO and Private Placement, net of issuance costs 2,248.2   2,248.2       2,248.2                          
Payment to non-controlling interest (8.0)                                   (8.0)  
Equity-based compensation plans [5] 45.3   45.3       45.3                          
Preferred dividend (64.1)   (64.1)       (64.1)                          
Accretion - Series A Preferred Stock (36.1)   (36.1)       (36.1)                          
Pension adjustments, net of tax expense (benefit) (96.3)   (96.3)                       (96.3)          
Change in cumulative translation adjustment, net of tax expense (income) 28.5 [1],[2]   25.3                   25.3           3.2  
Derivative financial instruments, net of tax expense (benefit) 0.7 [1],[3]   0.7                           0.7      
Balance at end of period at Dec. 31, 2020 3,583.9 [6]   3,525.6   0.0   4,310.2   (690.1)   0.0   26.2   (120.3)   (0.4)   58.3  
Tax benefit (expense) related to pension adjustment 39.0                                      
Foreign currency translation adjustments, tax expense (benefit) (1.6)                                      
Derivative financial instruments, tax expense (benefit) (2.8)                                      
Conversion of pre-IPO liability classified as equity-based awards to restricted stock units 0.2                                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Net income (loss) (65.9)   (71.7)           (71.7)                   5.8  
Payment to non-controlling interest (2.2)                                   (2.2)  
Shares issued for Bisnode acquisition 158.9   158.9       158.9                          
Equity-based compensation plans 31.0   31.0       31.3       (0.3)                  
Pension adjustments, net of tax expense (benefit) 108.4   108.4                       108.4          
Change in cumulative translation adjustment, net of tax expense (income) (76.6) [2]   (78.8)                   (78.8)           2.2  
Derivative financial instruments, net of tax expense (benefit) 7.8 [3]   7.8                           7.8      
Balance at end of period at Dec. 31, 2021 $ 3,745.3   $ 3,681.2   $ 0.0   $ 4,500.4   $ (761.8)   $ (0.3)   $ (52.6)   $ (11.9)   $ 7.4   $ 64.1  
[1] See Note 1 Basis of Presentation and Description of Business for further detail regarding the elimination of the International lag reporting.
[2] Tax Expense (Benefit) of $(1.6) million, $2.9 million, $1.8 million, and less than $0.1 million for the Successor year ended December 31, 2021, Successor year ended December 31, 2020, Successor period from January 1 to December 31, 2019, and for the Predecessor period from January 1 to February 7, 2019, respectively.
[3] Tax Expense (Benefit) of $2.8 million, $0.2 million, $(0.4) million, and $(0.1) million, for the Successor year ended December 31, 2021, Successor year ended December 31, 2020, Successor period from January 1 to December 31, 2019, and for the Predecessor period from January 1 to February 7, 2019, respectively.
[4] See Note 1 Basis of Presentation and Description of Business for further detail regarding the elimination of the International lag reporting
[5] Includes $0.2 million related to the conversion of pre-IPO liability classified equity-based awards into restricted stock units.
[6] See discussion in Note 1 - Basis of Presentation and Description of Business for further detail regarding the elimination of the International lag reporting.